|Bid||1,381.20 x 0|
|Ask||1,382.60 x 0|
|Day's Range||1,363.00 - 1,385.80|
|52 Week Range||1,190.80 - 1,696.60|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||13.24|
|Earnings Date||Jul 28, 2021|
|Forward Dividend & Yield||0.80 (5.84%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||1,644.50|
Results from a Phase 2 trial of the vaccine were promising enough for the two drugmakers to begin a 35,000-subject Phase 3 trial in the next few weeks, as Barron’s reported earlier. Sanofi (ticker: SNY) and Glaxo (GSK) have been developing the vaccine for over a year, but the program suffered a setback in December when the companies announced that an early trial suggested it might not be effective enough in older adults. On a press call held early Monday morning, Dr. Su-Peing Ng, Sanofi’s global head of medical for vaccines, said that levels of neutralizing antibodies were actually higher after a single dose of the vaccine in people who had previously been infected with the virus, than they were after two doses in people who had not been previously infected.
The delayed Covid-19 vaccine developed by French drugmaker Sanofi could be rolled out by the end of the year after early trials showed it was able to produce a strong immune response to the virus. Results from phase two study of the vaccine, which has been developed in partnership with GlaxoSmithKline, showed that the immune response of the 722 participants was comparable to that in people who had recovered from Covid-19. Just one shot of the vaccine produced a strong response in the trials, suggesting there is significant potential for the jab to be used as a booster, the companies said. The vaccine will now move to phase three trials and could be made available by the end of the year. Roger Connor, president of GSK's vaccine business, said: "We believe that this vaccine candidate can make a significant contribution to the ongoing fight against Covid-19 and will move to phase three as soon as possible to meet our goal of making it available before the end of the year." Sanofi and GSK's vaccine had initially been expected to receive regulatory approval in the first half of 2021, but it was delayed after failing to produce a strong response in the over 50s. The delay of the vaccine in December was seen as a major factor in Brussels' stuttering vaccine roll-out earlier this year after the EU placed a large order for the jab following pressure from Paris, where Sanofi is based. The European Commission ordered 300m doses of the vaccine in September, the second deal it struck after AstraZeneca. It only reached agreement with Pfizer and BioNTech in November despite the companies' vaccine having been recognised as a front-runner months earlier. German MP and epidemiologist Karl Lauterbach said: "France took care that not too much German vaccine was purchased in relation to the French vaccine." French ministers rejected the claims, calling them "unacceptable and false". Clement Beaune, France's European affairs minister, said at the time of the row: "It is absurd to play countries and laboratories off against each other because all countries need all the vaccines to vaccinate the maximum number of people between now and the summer." The UK has ordered 60m doses of the GSK and Sanofi vaccine, out of a total of more than 500m doses.
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic. The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine. The experimental vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers," it said in a statement. "A global pivotal Phase 3 study is expected to start in the coming weeks." The Phase 2 interim results showed 95% to 100% seroconversion following the second injection in all age groups (18 to 95 years old) across all doses, with acceptable tolerability and no safety concerns. A single dose generated high neutralizing antibody levels in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine. The company plans to initiate a global Phase 3 study with the 10µg dose in more than 35,000 adult participants. It will assess the efficacy of two vaccine formulations, including the D614 (Wuhan) and B.1.351 (South African) variants. In parallel, the companies intend to conduct booster studies with various variant formulations to assess if a lower vaccine dose generates a strong booster response regardless of the initial vaccine platform received. The vaccine's approval is expected in the fourth quarter of 2021, subject to regulations and Phase 3 outcome. Price Action: GSK shares are down 0.15% at $39.02, and SNY shares are up 0.42% are at $52.96 during the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaCureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal StudyFulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.